Miracor Medical

Executive Summary

Miracor Medical SA is a Belgian medical device company dedicated to improving outcomes for patients with severe cardiac diseases. Founded in 2008 and headquartered in Zaventem, the company has developed the PiCSO® Impulse System, a novel therapy for acute myocardial infarction (MI). This system is designed to reduce infarct size and prevent heart failure by applying intermittent coronary sinus occlusion during primary PCI. The technology addresses a significant unmet need in cardiology, as current treatments for acute MI often result in substantial myocardial damage despite timely reperfusion. Miracor's approach has the potential to set a new standard of care, offering a minimally invasive adjunct to existing procedures. The company is private and has not disclosed total funding or valuation, but its focus on a disruptive therapy in a large market positions it as an attractive candidate for investment or acquisition.

Upcoming Catalysts (preview)

• Q4 2026FDA Approval or Breakthrough Device Designation for PiCSO System70% success
• Q2 2026Publication of Pivotal Clinical Trial Results60% success
• TBDStrategic Partnership or Licensing Deal with Major Cardiovascular Company50% success